【GE CHENG News】A turnround in Sito Bio's RMB 226 million patent lawsuit with opponent's patent all invalid

On August 24th,2026, Shandong Sito Bio-technology CO., LTD (hereinafter "Sito Bio”) disclosed new developments for a patent litigation that CNIPA declaring the patent for Hunan Norchem Pharmaceutical Co., Ltd (short as "Norchem")’s "Preparation Method of 16β-Methyl Steroid Compounds" (ZL201610223758.0) entirely invalid.

 

This ruling means that the legal basis for the patent infringement lawsuit against Sito Bio and its subsidiary Shandong Sirui Pharmaceutical Co., Ltd. (short as “Sirui Pharma”) filed by Norchem for RMB 226 million has consequently changed.

 

Invalidation of the patent in suit results in a new turn in the situation of the RMB 226 million lawsuit

 

Sito Bio is a ChiNext-listed company on the A-share market, specializing in the R&D and production of steroid drug intermediates, with revenue of approximately RMB 1.017 billion in 2025. Sirui Pharma is its controlled subsidiary. Norchem was established in 2010, operates in the same segment of the industry chain as Sito Bio, with the two parties in direct horizontal competition.

 

In February this year, Norchem sued Sito Bio and its controlling subsidiary, Sirui Pharma, at the Shandong High People's Court over a dispute concerning infringement of invention patent rights, alleging that an intermediate product produced by the two defendants fell within the protection scope of its process invention patents, and requesting the court to order the defendants to immediately cease infringement and compensate for losses, with the amount in dispute totaling RMB 226 million.

 

The case involves two invention patents, "Preparation Method of 21-Halogenated Steroid Compounds" (ZL201810060392.9) and "Preparation Method of 16β-Methyl Steroid Compounds" (ZL201610223758.0). According to the industry reports, the products at issue are closely related to the core preparation process of a key dexamethasone intermediate.

 

Sito Bio responded that its relevant products were all independently developed, that it did not accept the plaintiff's claims, emphasizing that the patents in the case involve only one intermediate product and account for a low proportion of revenue. Sito Bio and Sirui Pharma chose to file invalidation requests with the CNIPA against both patents at issue after receiving the litigation materials.

 

On August 24, Sito Bio announced receiving the Examination Decision on Request for Invalidation (No. 660981), declaring the patent (ZL201610223758.0) entirely invalid.  Meanwhile, the invalidation request filed against another patent involved in the case, ZL201810060392.9, is still under examination. 

 

For this lawsuit at the case-filing and acceptance stage which has not yet been heard—this invalidation decision is tantamount to " eliminate the root cause." How the court will subsequently adjudicate this lawsuit over "rights already lost" remains to be seen.

 

Sito Bio's "two-front battle" switching between offense and defense

 

However, in general, this is just one of two major intellectual property disputes Sito Bio has been involved in over the past 6 months—in the same court, it is both a defendant in a patent infringement suit and a plaintiff in a trade secrets case claiming RMB 320 million. This swapping of roles between offense and defense is precisely a microcosm of the changing competitive landscape in the steroid industry.

 

In the first half of 2026, Sito Bio sued Shenyang Botai Biopharmaceutical Co., Ltd. (hereinafter "Botai Bio") and four other defendants for trade secret infringement with the Shandong High People's Court as the plaintiff.


According to the facts disclosed by Sito Bio, the departed personnel involved had previously been found to have committed the crime of infringing trade secrets. It alleged that the relevant personnel were instructed to obtain the company's technical secrets for establishing Botai Bio to operate competing products of the same kind, and accordingly requested the court to order all defendants to immediately cease infringement and to pay RMB 320 million in compensation for economic losses.

 

So far, while initiating the RMB 320 million trade secret claim as the plaintiff, Sito Bio is also defending itself as the defendant in another patent infringement lawsuit involving RMB 226 million.

 

The two fronts are not isolated from each other. Patents and trade secrets are naturally the two most core types of intangible assets for technology-based enterprises, and also the most common battlegrounds between competitors. An enterprise being simultaneously on offense and defense on both fronts shows that the technology competition in its field has become intensely fierce and the talent mobility within the industry has become highly frequent.

 

From IPRdaily

September 8th, 2026



Back